MedTrace Logo

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia

NCT02578849 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2015-10-19

No results posted yet for this study

Summary

The aims of this proposal include tests of hypotheses of the pathogenetic mechanisms of noradrenergic neurotransmission in Parkinson's disease in vivo, using positron emission tomography of patients with early and advanced Parkinson's disease with or without 3,4 L-dihydroxyphenylalanine (L-DOPA) - induced dyskinesia or co-morbid depression, and evaluation of whether these mechanisms can be influenced therapeutically.

Hypotheses:

1. The investigators argue that release in human cortical and subcortical brain regions of norepinephrine (NE) derived from metabolism of exogenousL-DOPA is greater in Parkinson's disease patients with L-DOPA- induced dyskinesia than in patients without this complication. This hypothesis will be tested by measuring antagonist \[11C\]yohimbine binding to alpha-2 adrenoceptors before and after L-DOPA challenge.
2. If so, it is argued that the greater rise of norepinephrine, measured as \[11C\]yohimbine displacement after L-DOPA challenge, is the result of down-regulation or loss of norepinephrine transporters. This hypothesis will be tested by measuring the binding of \[11C\]MeNER, a tracer of norepinephrine transporters.
3. If so, the investigators argue that the greater decline of \[11C\]MeNER binding is significantly correlated to the symptoms of Parkinson's disease, as proof that patients with more severe loss of noradrenergic terminals exhibit more severe motor deficits.

Conditions

  • Parkinson´s Disease

Interventions

DRUG

L-DOPA

Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.

Sponsors & Collaborators

  • University of Copenhagen

    collaborator OTHER

  • Aarhus University Hospital

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02578849 on ClinicalTrials.gov